Cargando…
The time window for the reversal of depigmentation from aggravation to recovery in a non-small-cell lung cancer patient with pre-existing vitiligo using anti-programmed cell death-1 therapy: A case report
Immune checkpoint inhibitors have made remarkable breakthroughs in the treatment of lung cancer, bringing significant survival benefits to the patients. A number of adverse events aggravated by immunotherapy in patients with pre-existing autoimmune diseases have been reported in the past, especially...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9424493/ https://www.ncbi.nlm.nih.gov/pubmed/36052082 http://dx.doi.org/10.3389/fimmu.2022.946829 |
_version_ | 1784778233570394112 |
---|---|
author | Gao, Zhiru Xu, Yinghui Zu, Jianjiao Wang, Xu Sun, Chao Qiu, Shi Guo, Ye Ma, Kewei |
author_facet | Gao, Zhiru Xu, Yinghui Zu, Jianjiao Wang, Xu Sun, Chao Qiu, Shi Guo, Ye Ma, Kewei |
author_sort | Gao, Zhiru |
collection | PubMed |
description | Immune checkpoint inhibitors have made remarkable breakthroughs in the treatment of lung cancer, bringing significant survival benefits to the patients. A number of adverse events aggravated by immunotherapy in patients with pre-existing autoimmune diseases have been reported in the past, especially skin toxicity, such as rash, pruritus, erythema, and vitiligo. However, whether the exacerbated autoimmune disease is reversible and when it will return to its original state after immunotherapy discontinuation is still inconclusive. In our report, we described a patient diagnosed with non-small cell lung cancer whose vitiligo was stable for about 10 years. We followed up and observed the patient’s skin depigmentation for the complete time window, from aggravation of application anti-programmed cell death-1 receptor antibody (anti-PD-1 antibody) to recovery after the withdrawal. We presented the objective images at particular time points using reflectance confocal microscopy and wood’s light. We found that the use of anti-PD-1 antibody aggravated in skin toxicity, but it was reversible, the time window from the beginning to recovery status was approximately 9 months. We used this real case scenario to explain the relationships between immunotherapy and autoimmune diseases. |
format | Online Article Text |
id | pubmed-9424493 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-94244932022-08-31 The time window for the reversal of depigmentation from aggravation to recovery in a non-small-cell lung cancer patient with pre-existing vitiligo using anti-programmed cell death-1 therapy: A case report Gao, Zhiru Xu, Yinghui Zu, Jianjiao Wang, Xu Sun, Chao Qiu, Shi Guo, Ye Ma, Kewei Front Immunol Immunology Immune checkpoint inhibitors have made remarkable breakthroughs in the treatment of lung cancer, bringing significant survival benefits to the patients. A number of adverse events aggravated by immunotherapy in patients with pre-existing autoimmune diseases have been reported in the past, especially skin toxicity, such as rash, pruritus, erythema, and vitiligo. However, whether the exacerbated autoimmune disease is reversible and when it will return to its original state after immunotherapy discontinuation is still inconclusive. In our report, we described a patient diagnosed with non-small cell lung cancer whose vitiligo was stable for about 10 years. We followed up and observed the patient’s skin depigmentation for the complete time window, from aggravation of application anti-programmed cell death-1 receptor antibody (anti-PD-1 antibody) to recovery after the withdrawal. We presented the objective images at particular time points using reflectance confocal microscopy and wood’s light. We found that the use of anti-PD-1 antibody aggravated in skin toxicity, but it was reversible, the time window from the beginning to recovery status was approximately 9 months. We used this real case scenario to explain the relationships between immunotherapy and autoimmune diseases. Frontiers Media S.A. 2022-08-16 /pmc/articles/PMC9424493/ /pubmed/36052082 http://dx.doi.org/10.3389/fimmu.2022.946829 Text en Copyright © 2022 Gao, Xu, Zu, Wang, Sun, Qiu, Guo and Ma https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Gao, Zhiru Xu, Yinghui Zu, Jianjiao Wang, Xu Sun, Chao Qiu, Shi Guo, Ye Ma, Kewei The time window for the reversal of depigmentation from aggravation to recovery in a non-small-cell lung cancer patient with pre-existing vitiligo using anti-programmed cell death-1 therapy: A case report |
title | The time window for the reversal of depigmentation from aggravation to recovery in a non-small-cell lung cancer patient with pre-existing vitiligo using anti-programmed cell death-1 therapy: A case report |
title_full | The time window for the reversal of depigmentation from aggravation to recovery in a non-small-cell lung cancer patient with pre-existing vitiligo using anti-programmed cell death-1 therapy: A case report |
title_fullStr | The time window for the reversal of depigmentation from aggravation to recovery in a non-small-cell lung cancer patient with pre-existing vitiligo using anti-programmed cell death-1 therapy: A case report |
title_full_unstemmed | The time window for the reversal of depigmentation from aggravation to recovery in a non-small-cell lung cancer patient with pre-existing vitiligo using anti-programmed cell death-1 therapy: A case report |
title_short | The time window for the reversal of depigmentation from aggravation to recovery in a non-small-cell lung cancer patient with pre-existing vitiligo using anti-programmed cell death-1 therapy: A case report |
title_sort | time window for the reversal of depigmentation from aggravation to recovery in a non-small-cell lung cancer patient with pre-existing vitiligo using anti-programmed cell death-1 therapy: a case report |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9424493/ https://www.ncbi.nlm.nih.gov/pubmed/36052082 http://dx.doi.org/10.3389/fimmu.2022.946829 |
work_keys_str_mv | AT gaozhiru thetimewindowforthereversalofdepigmentationfromaggravationtorecoveryinanonsmallcelllungcancerpatientwithpreexistingvitiligousingantiprogrammedcelldeath1therapyacasereport AT xuyinghui thetimewindowforthereversalofdepigmentationfromaggravationtorecoveryinanonsmallcelllungcancerpatientwithpreexistingvitiligousingantiprogrammedcelldeath1therapyacasereport AT zujianjiao thetimewindowforthereversalofdepigmentationfromaggravationtorecoveryinanonsmallcelllungcancerpatientwithpreexistingvitiligousingantiprogrammedcelldeath1therapyacasereport AT wangxu thetimewindowforthereversalofdepigmentationfromaggravationtorecoveryinanonsmallcelllungcancerpatientwithpreexistingvitiligousingantiprogrammedcelldeath1therapyacasereport AT sunchao thetimewindowforthereversalofdepigmentationfromaggravationtorecoveryinanonsmallcelllungcancerpatientwithpreexistingvitiligousingantiprogrammedcelldeath1therapyacasereport AT qiushi thetimewindowforthereversalofdepigmentationfromaggravationtorecoveryinanonsmallcelllungcancerpatientwithpreexistingvitiligousingantiprogrammedcelldeath1therapyacasereport AT guoye thetimewindowforthereversalofdepigmentationfromaggravationtorecoveryinanonsmallcelllungcancerpatientwithpreexistingvitiligousingantiprogrammedcelldeath1therapyacasereport AT makewei thetimewindowforthereversalofdepigmentationfromaggravationtorecoveryinanonsmallcelllungcancerpatientwithpreexistingvitiligousingantiprogrammedcelldeath1therapyacasereport AT gaozhiru timewindowforthereversalofdepigmentationfromaggravationtorecoveryinanonsmallcelllungcancerpatientwithpreexistingvitiligousingantiprogrammedcelldeath1therapyacasereport AT xuyinghui timewindowforthereversalofdepigmentationfromaggravationtorecoveryinanonsmallcelllungcancerpatientwithpreexistingvitiligousingantiprogrammedcelldeath1therapyacasereport AT zujianjiao timewindowforthereversalofdepigmentationfromaggravationtorecoveryinanonsmallcelllungcancerpatientwithpreexistingvitiligousingantiprogrammedcelldeath1therapyacasereport AT wangxu timewindowforthereversalofdepigmentationfromaggravationtorecoveryinanonsmallcelllungcancerpatientwithpreexistingvitiligousingantiprogrammedcelldeath1therapyacasereport AT sunchao timewindowforthereversalofdepigmentationfromaggravationtorecoveryinanonsmallcelllungcancerpatientwithpreexistingvitiligousingantiprogrammedcelldeath1therapyacasereport AT qiushi timewindowforthereversalofdepigmentationfromaggravationtorecoveryinanonsmallcelllungcancerpatientwithpreexistingvitiligousingantiprogrammedcelldeath1therapyacasereport AT guoye timewindowforthereversalofdepigmentationfromaggravationtorecoveryinanonsmallcelllungcancerpatientwithpreexistingvitiligousingantiprogrammedcelldeath1therapyacasereport AT makewei timewindowforthereversalofdepigmentationfromaggravationtorecoveryinanonsmallcelllungcancerpatientwithpreexistingvitiligousingantiprogrammedcelldeath1therapyacasereport |